Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory, and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next-generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain an […]Read More
Shots: Molecular Templates (MTEM) to receive $38M up front including an equity investment, up to $522M as development, regulatory, commercial milestones, option payment for two targets and royalties on sales of products MTEM will conduct research activities to discover a new conditioning regimen utilizing its engineered toxin body (ETB) platform for up to two targets […]Read More
Shots: Takeda will provide upfront of $30M and to pay royalties on commercialization. CD38-Targeted ETBs’ development cost will be shared equally between both the parties Molecular Templates will receive development, regulatory and commercial milestone payments of up to $632.5M if company exercise its co-development option, or $337.5M if it does not exercise or opts out […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
